Methods for Assaying a Bodily Sample of a Subject

A method comprising:

• (a) obtaining a bodily sample from a subject;
• (b) assaying the bodily sample, wherein the assaying comprises detecting a level of analytes in the bodily sample, wherein the analytes comprise nucleic acids, proteins, or metabolites, wherein the analytes comprise at least five biomarkers selected from the group of biomarkers listed in Table 1A;
• (c) processing the level of analytes in the sample comprising the at least five biomarkers (i) using a trained machine learning algorithm or (ii) against a reference level;
• (d) determining that the subject is affected with an asymptomatic or prodromal phase of Alzheimer's disease, based at least in part on the processing in (c);
• and
• (e) responsive to the determining in (d), administering an effective amount of a drug treatment to the subject sufficient to treat the subject for the asymptomatic or prodromal phase of Alzheimer's disease,
• wherein the drug treatment is selected from the group consisting of:
• a beta-secretase 1 (BACE1) inhibitor, an inhibitor of the aggregation and seeding of Tau or Aβ, an anxiolytic drug, an anti-amyloid agent, an anti-Tau agent, a synaptic plasticity enhancer, a neuroprotection enhancer, and a beta-secretase inhibitor.